CDKN2A / p14ARF antibody

GeneTex

CDKN2A / p14ARF antibody

9

WB: 1:100 - 1:2000. ICC/IF: 1:50 - 1:200. IHC-P: 1:10 - 1:500. IHC-Fr: 1:10 - 1:500. FACS: 1:400. ELISA: 1:100 - 1:2000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.

Flow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ELISA, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin

Research Use Only

Polyclonal

1 mg/ml

Unconjugated

CDKN2A

cyclin dependent kinase inhibitor 2A

alternative reading frame; ARF; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; cell cycle negative regulator beta; CMM2; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); INK4; INK4A; MLM; MTS1; MTS-1; multiple tumor suppressor 1; P14; P14ARF; P16; P16INK4; P16INK4A; P16-INK4A; P19; P19ARF; TP16

Rabbit

IgG

Cyclin-dependent kinase inhibitor 2A

The INK4a-ARF locus is comprised of two tumor suppressors, p16INK4a and p14ARF. These two proteins are encoded through differential splicing of alternative first exons. The p16INK4a (exon 1alpha) protein inhibits the cyclin D-dependent kinases (CDK) that control the phosphorylation of the Rb protein and cell proliferation. The p14ARF gene product complexes with the MDM2 protein within the nucleus, thus modulating the activity of the p53 protein. P14ARF is a potent tumor suppressor in the presence of wild-type p53, while mutant p53 substantially reduces growth inhibition by p14ARF.

Human, Mouse

-20°C or -80°C,2°C to 8°C

12352203